姑息治疗与安宁疗护基本用药指南

2021-04-02 中国全科医学.2021.24(14):1717-1733.

姑息治疗与安宁疗护是通过多学科协作的模式,有效改善患者的痛苦症状、提高生活质量,直至其舒适、有尊严离世的新兴临床学科,适用于各年龄阶段,罹患现代医学无法治愈,并伴有躯体和/ 或精神心理症状,严重影响生

中文标题:

姑息治疗与安宁疗护基本用药指南

发布机构:

发布日期:

2021-04-02

简要介绍:

姑息治疗与安宁疗护是通过多学科协作的模式,有效改善患者的痛苦症状、提高生活质量,直至其舒适、有尊严离世的新兴临床学科,适用于各年龄阶段,罹患现代医学无法治愈,并伴有躯体和/ 或精神心理症状,严重影响生活质量的疾病终末期和临终期患者。合理使用药物是姑息治疗与安宁疗护中最为重要的内容之一,因此,指南工作组依照国际指南的制定标准、结合国内外相关研究和临床实践,制订了我国首部《姑息治疗与安宁疗护基本用药指南》。该指南围绕各种疾病终末期和临终期患者常见的33 个全身性和各系统的躯体、精神心理症状及难治性症状,推荐23 种治疗药物,其中20 种药物收录于我国现行《国家基本药物目录》。为便于广大医务人员参阅学习,指南详细阐述了姑息治疗与安宁疗护专科的基本理论、临床用药原则、相关药物的用法用量和注意事项等内容。该指南的制定有助于提升各临床学科对疾病终末期和临终患者的诊疗服务质量,是确保患者获得舒适与尊严性医疗服务的基本保障,同时填补了我国姑息治疗与安宁疗护学科发展的空白。

相关资料下载:
[AttachmentFileName(sort=1, fileName=姑息治疗与安宁疗护基本用药指南_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=57b001c002089a74, title=姑息治疗与安宁疗护基本用药指南, enTitle=, guiderFrom=中国全科医学.2021.24(14):1717-1733., authorId=0, author=, summary=姑息治疗与安宁疗护是通过多学科协作的模式,有效改善患者的痛苦症状、提高生活质量,直至其舒适、有尊严离世的新兴临床学科,适用于各年龄阶段,罹患现代医学无法治愈,并伴有躯体和/ 或精神心理症状,严重影响生, cover=https://img.medsci.cn/2021426/1619448716418_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Fri Apr 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>姑息治疗与安宁疗护是通过多学科协作的模式,有效改善患者的痛苦症状、提高生活质量,直至其舒适、有尊严离世的新兴临床学科,适用于各年龄阶段,罹患现代医学无法治愈,并伴有躯体和/ 或精神心理症状,严重影响生活质量的疾病终末期和临终期患者。合理使用药物是姑息治疗与安宁疗护中最为重要的内容之一,因此,指南工作组依照国际指南的制定标准、结合国内外相关研究和临床实践,制订了我国首部《姑息治疗与安宁疗护基本用药指南》。该指南围绕各种疾病终末期和临终期患者常见的33 个全身性和各系统的躯体、精神心理症状及难治性症状,推荐23 种治疗药物,其中20 种药物收录于我国现行《国家基本药物目录》。为便于广大医务人员参阅学习,指南详细阐述了姑息治疗与安宁疗护专科的基本理论、临床用药原则、相关药物的用法用量和注意事项等内容。该指南的制定有助于提升各临床学科对疾病终末期和临终患者的诊疗服务质量,是确保患者获得舒适与尊严性医疗服务的基本保障,同时填补了我国姑息治疗与安宁疗护学科发展的空白。</p> </div> </div> </div>, tagList=[TagDto(tagId=343, tagName=姑息治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=19, categoryName=老年医学, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=343, guiderKeyword=姑息治疗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13153, appHits=237, showAppHits=0, pcHits=776, showPcHits=12916, likes=6, shares=25, comments=19, approvalStatus=1, publishedTime=Mon Apr 26 23:27:36 CST 2021, publishedTimeString=2021-04-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Apr 26 22:52:15 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 14:23:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=姑息治疗与安宁疗护基本用药指南_.pdf)])
姑息治疗与安宁疗护基本用药指南_.pdf
下载请点击:
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2127199, encodeId=fd2a212e199cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8bf3847840, createdName=1376a07fm02暂无昵称, createdTime=Thu Apr 20 08:43:21 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1051743, encodeId=5bda1051e4347, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:09:29 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013812, encodeId=83dc10138129c, content=加载加载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013811, encodeId=423a101381160, content=好的好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:14 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007287, encodeId=adef100e287fb, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/759caf56c3484eacbfe31dd805343725/ef96d9acb98241bcbae5f1d696677e20.jpg, createdBy=2d545571357, createdName=ms4000000843810017, createdTime=Thu Aug 12 15:01:43 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2023-04-20 1376a07fm02暂无昵称 来自广东省

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2127199, encodeId=fd2a212e199cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8bf3847840, createdName=1376a07fm02暂无昵称, createdTime=Thu Apr 20 08:43:21 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1051743, encodeId=5bda1051e4347, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:09:29 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013812, encodeId=83dc10138129c, content=加载加载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013811, encodeId=423a101381160, content=好的好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:14 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007287, encodeId=adef100e287fb, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/759caf56c3484eacbfe31dd805343725/ef96d9acb98241bcbae5f1d696677e20.jpg, createdBy=2d545571357, createdName=ms4000000843810017, createdTime=Thu Aug 12 15:01:43 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    值得学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2127199, encodeId=fd2a212e199cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8bf3847840, createdName=1376a07fm02暂无昵称, createdTime=Thu Apr 20 08:43:21 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1051743, encodeId=5bda1051e4347, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:09:29 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013812, encodeId=83dc10138129c, content=加载加载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013811, encodeId=423a101381160, content=好的好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:14 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007287, encodeId=adef100e287fb, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/759caf56c3484eacbfe31dd805343725/ef96d9acb98241bcbae5f1d696677e20.jpg, createdBy=2d545571357, createdName=ms4000000843810017, createdTime=Thu Aug 12 15:01:43 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-09-02 学者

    加载加载

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2127199, encodeId=fd2a212e199cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8bf3847840, createdName=1376a07fm02暂无昵称, createdTime=Thu Apr 20 08:43:21 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1051743, encodeId=5bda1051e4347, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:09:29 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013812, encodeId=83dc10138129c, content=加载加载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013811, encodeId=423a101381160, content=好的好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:14 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007287, encodeId=adef100e287fb, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/759caf56c3484eacbfe31dd805343725/ef96d9acb98241bcbae5f1d696677e20.jpg, createdBy=2d545571357, createdName=ms4000000843810017, createdTime=Thu Aug 12 15:01:43 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-09-02 学者

    好的好的

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2127199, encodeId=fd2a212e199cd, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8bf3847840, createdName=1376a07fm02暂无昵称, createdTime=Thu Apr 20 08:43:21 CST 2023, time=2023-04-20, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1051743, encodeId=5bda1051e4347, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 00:09:29 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013812, encodeId=83dc10138129c, content=加载加载, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1013811, encodeId=423a101381160, content=好的好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201128/8bd43ecc40d747e890c41c35a068882e/9f274b8360b04bf085fc42125c37f102.jpg, createdBy=c4bc5437608, createdName=学者, createdTime=Thu Sep 02 17:10:14 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007287, encodeId=adef100e287fb, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/759caf56c3484eacbfe31dd805343725/ef96d9acb98241bcbae5f1d696677e20.jpg, createdBy=2d545571357, createdName=ms4000000843810017, createdTime=Thu Aug 12 15:01:43 CST 2021, time=2021-08-12, status=1, ipAttribution=)]
    2021-08-12 ms4000000843810017

    好文

    0

拓展阅读

2014 ESMO临床实践指南:姑息治疗-晚期护理计划

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2014-09-17

2014EPCRC:精神关怀指南 V1.0

欧洲姑息治疗研究协作组(EPCRC,The European Palliative Care Research Collaborative) · 2014-06-11

2018 丹麦呼吸学会意见书:慢性进行性非恶性肺病患者的姑息治疗

丹麦呼吸学会(Danish respiratory society) · 2018-10-16

2019 EAPC立场声明:心衰患者的姑息治疗

欧洲姑息治疗学会(EAPC,European Association for Palliative Care) · 2019-08-06

2019 欧洲初级医疗论坛意见书:初级医疗保健中的姑息治疗

欧洲初级医疗论坛(European Forum for Primary Care) · 2019-09-18